No Data
Zhongtai: The implementation of the tenth batch of centralized procurement is expected to accelerate the clearance of generic drugs. Commercial insurance is an important incremental logic in the pharmaceutical Sector.
It is recommended to keep a close eye on the progress and implementation of commercial insurance, as improvements in the payment sector are expected to bring about a significant market trend in the Pharmaceutical Sector, with opportunities for recovery and reversal in hospital pharmaceuticals, diagnostics, and Medical Devices.
Nuo Tai Biotechnology (688076.SH) has reached a global strategy cooperation with SSC for the application of electrostatic spray drying technology in the commercial production of peptide active pharmaceutical ingredients.
Nuotai Biology (688076.SH) announced that the company recently signed an agreement with Spr... Company in the usa.
Northeast Bio (688076.SH) has signed a letter of intent for strategic cooperation with the usa Spry Spray Systems company.
On December 8, Glonghui reported that Nuotai Biological (688076.SH) announced that it has recently signed a "Global Strategy Cooperation Intent Letter" with Spraying Systems Co. (hereinafter referred to as "SSC") from the usa, reaching a strategic cooperation on the application of electrostatic spray drying technology in the commercial production field of peptide active pharmaceutical ingredients. According to the disclosure, SSC is a global leader in the professional manufacturing of industrial spray nozzles and automatic spray systems, and its patented PolarDry technology is an innovative electrostatic drying technology that achieves low-temperature and efficient drying while maintaining product quality.
Southwest Securities: CXO industry revenues are recovering season by season, but the demand for preclinical services still needs to be restored.
From a short-term perspective, commercial orders continue to be digested, putting pressure on the apparent performance of CDMO; overseas mature CXO clinical pipelines are steadily advancing, and the preclinical demand still needs to be restored.
Declining Stock and Solid Fundamentals: Is The Market Wrong About Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076)?
Concept mining | Simgeglutide weight loss drug officially launched in China, multiple e-commerce platforms have gone online
The market has broad prospects
Earnings Not Telling The Story For Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (SHSE:688076) After Shares Rise 26%
